Geovax Labs Inc (GOVX) 0.0808 $GOVX
GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge
Marketwire Canada - Wed Jun 01, 8:00AM CDT
Single Dose Provided 100% Protection, Tetravalent Hemorrhagic Fever Virus Vaccine Under Development
GeoVax Observes HIV Vaccine Awareness Day and Prepares for Next Human Clinical Trial of GOVX-B11
Marketwired - Wed May 18, 8:00AM CDT
Recognizing the Support of the National Institutes of Health and the HIV Vaccine Trials Network in Advancing GeoVax's HIV Vaccine Development Efforts
GeoVax Labs, Inc. Issues Letter to Shareholders
Marketwire Canada - Mon May 09, 8:00AM CDT
Updates on Zika, Ebola and HIV Vaccine Programs and Cancer Immunotherapy Initiative
GeoVax Reports 2016 First Quarter Financial Results
Marketwired - Wed May 04, 8:00AM CDT
ATLANTA, GA--(Marketwired - May 4, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016.
GeoVax Presents at Zika Virus Scientific Conference
Marketwired - Mon May 02, 11:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, presented today at the conference Bridging the Sciences: Zika Virus, held at the Emory Conference Center in Atlanta, Georgia.
GeoVax Provides Update on Zika Vaccine Program
Marketwired - Mon Apr 18, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, provided an update today on its program to develop a safe and effective vaccine to prevent Zika virus infection in humans. No approved vaccine currently exists for this rapidly spreading mosquito-borne disease.
GeoVax Awarded $1.4M NIH Grant
Marketwired - Thu Apr 14, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Phase II Small Business Innovative Research (SBIR) grant in support of its clade B HIV vaccine development program for the Americas. The grant award of $740,456 will fund the first year of a two-year project period with a total budget of $1,398,615. The grant, entitled "Enhancing Protective Antibody Responses for a DNA/MVA HIV Vaccine", will support preclinical studies testing the ability of a bivalent (two component) protein boost to enhance the efficacy of the GeoVax Clade B HIV vaccine (GOVX-B11).
GeoVax Recognizes National Youth HIV & AIDS Awareness Day
Marketwired - Fri Apr 08, 8:00AM CDT
On Sunday, April 10, individuals and organizations across the country will observe National Youth HIV & AIDS Awareness Day, a day set aside to recognize the impact of the HIV/AIDS epidemic on young people. GeoVax Labs, Inc. (OTCQB: GOVX) is commemorating the day by bringing attention to the alarming rate of infections among US youth and the need for an HIV vaccine.
GeoVax Extends Research Collaborations on Zika Vaccine
Marketwired - Wed Mar 30, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has entered into a Research Collaboration Agreement with the Centers for Disease Control and Prevention (CDC) to evaluate the immunogenicity and protective efficacy of its Zika virus vaccine.
GeoVax Applauds Passage of Senate Bill to Accelerate Development of Zika Virus Vaccines
Marketwired - Mon Mar 21, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, applauded Senate passage of legislation co-sponsored by U.S. Senator Johnny Isakson, R-Ga., that would add Zika virus to an FDA program that helps expedite vaccine and drug development.
GeoVax Reports 2015 Year-End Financial Results and Provides Corporate Update
Marketwired - Wed Mar 16, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2015.
Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates
Marketwired - Mon Mar 07, 8:00AM CST
GeoVax Labs. Inc. (OTCQB: GOVX) today announced that the simian analogue of the company's human immunodeficiency virus (HIV) vaccine, GOVX-B11, provided a 76 percent reduction in per exposure risk of simian immunodeficiency virus (SIV) infection in young adult rhesus macaques. Per exposure risk was assessed over 12 weekly rectal exposures. The study, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), also showed the vaccine providing much better protection for young adult than middle-aged and older macaques.
GeoVax Labs, Inc. (OTCQB: GOVX) Racing to Develop Vaccine for Zika Virus
ACCESSWIRE - Tue Feb 09, 7:55AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / GeoVax Labs, Inc. (OTCQB: GOVX) shares spiked last week after the company announced it would pursue development of a vaccine for the Zika Virus. The company shares traded just under $0.08 before the announcement and immediately jumped to over $0.12 per share. As investors took profits the GOVX shares settled back to the $0.08 range.
GeoVax Recognizes National Black HIV/AIDS Awareness Day
Marketwired - Fri Feb 05, 8:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX). On Sunday, February 7, individuals and organizations across the country will observe National Black HIV/AIDS Awareness Day 2016. GeoVax plans to commemorate the day by celebrating the progress made toward the development of a vaccine against HIV, recognizing the work yet to be done, and bringing attention to the continued HIV epidemic in the United States and the disproportionate impact of the disease on African Americans.
GeoVax to Develop Vaccine Against Zika Virus
Marketwired - Wed Feb 03, 8:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has begun a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform. The company believes that it can rapidly advance a vaccine candidate to human clinical testing.
GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge
Marketwire Canada - Wed Jun 01, 8:00AM CDT
Single Dose Provided 100% Protection, Tetravalent Hemorrhagic Fever Virus Vaccine Under Development
GeoVax Observes HIV Vaccine Awareness Day and Prepares for Next Human Clinical Trial of GOVX-B11
Marketwired - Wed May 18, 8:00AM CDT
Recognizing the Support of the National Institutes of Health and the HIV Vaccine Trials Network in Advancing GeoVax's HIV Vaccine Development Efforts
GeoVax Labs, Inc. Issues Letter to Shareholders
Marketwire Canada - Mon May 09, 8:00AM CDT
Updates on Zika, Ebola and HIV Vaccine Programs and Cancer Immunotherapy Initiative
GeoVax Reports 2016 First Quarter Financial Results
Marketwired - Wed May 04, 8:00AM CDT
ATLANTA, GA--(Marketwired - May 4, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016.
GeoVax Presents at Zika Virus Scientific Conference
Marketwired - Mon May 02, 11:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, presented today at the conference Bridging the Sciences: Zika Virus, held at the Emory Conference Center in Atlanta, Georgia.
GeoVax Provides Update on Zika Vaccine Program
Marketwired - Mon Apr 18, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, provided an update today on its program to develop a safe and effective vaccine to prevent Zika virus infection in humans. No approved vaccine currently exists for this rapidly spreading mosquito-borne disease.
GeoVax Awarded $1.4M NIH Grant
Marketwired - Thu Apr 14, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Phase II Small Business Innovative Research (SBIR) grant in support of its clade B HIV vaccine development program for the Americas. The grant award of $740,456 will fund the first year of a two-year project period with a total budget of $1,398,615. The grant, entitled "Enhancing Protective Antibody Responses for a DNA/MVA HIV Vaccine", will support preclinical studies testing the ability of a bivalent (two component) protein boost to enhance the efficacy of the GeoVax Clade B HIV vaccine (GOVX-B11).
GeoVax Recognizes National Youth HIV & AIDS Awareness Day
Marketwired - Fri Apr 08, 8:00AM CDT
On Sunday, April 10, individuals and organizations across the country will observe National Youth HIV & AIDS Awareness Day, a day set aside to recognize the impact of the HIV/AIDS epidemic on young people. GeoVax Labs, Inc. (OTCQB: GOVX) is commemorating the day by bringing attention to the alarming rate of infections among US youth and the need for an HIV vaccine.
GeoVax Extends Research Collaborations on Zika Vaccine
Marketwired - Wed Mar 30, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has entered into a Research Collaboration Agreement with the Centers for Disease Control and Prevention (CDC) to evaluate the immunogenicity and protective efficacy of its Zika virus vaccine.
GeoVax Applauds Passage of Senate Bill to Accelerate Development of Zika Virus Vaccines
Marketwired - Mon Mar 21, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, applauded Senate passage of legislation co-sponsored by U.S. Senator Johnny Isakson, R-Ga., that would add Zika virus to an FDA program that helps expedite vaccine and drug development.
GeoVax Reports 2015 Year-End Financial Results and Provides Corporate Update
Marketwired - Wed Mar 16, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2015.
Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates
Marketwired - Mon Mar 07, 8:00AM CST
GeoVax Labs. Inc. (OTCQB: GOVX) today announced that the simian analogue of the company's human immunodeficiency virus (HIV) vaccine, GOVX-B11, provided a 76 percent reduction in per exposure risk of simian immunodeficiency virus (SIV) infection in young adult rhesus macaques. Per exposure risk was assessed over 12 weekly rectal exposures. The study, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), also showed the vaccine providing much better protection for young adult than middle-aged and older macaques.
GeoVax Labs, Inc. (OTCQB: GOVX) Racing to Develop Vaccine for Zika Virus
ACCESSWIRE - Tue Feb 09, 7:55AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / GeoVax Labs, Inc. (OTCQB: GOVX) shares spiked last week after the company announced it would pursue development of a vaccine for the Zika Virus. The company shares traded just under $0.08 before the announcement and immediately jumped to over $0.12 per share. As investors took profits the GOVX shares settled back to the $0.08 range.
GeoVax Recognizes National Black HIV/AIDS Awareness Day
Marketwired - Fri Feb 05, 8:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX). On Sunday, February 7, individuals and organizations across the country will observe National Black HIV/AIDS Awareness Day 2016. GeoVax plans to commemorate the day by celebrating the progress made toward the development of a vaccine against HIV, recognizing the work yet to be done, and bringing attention to the continued HIV epidemic in the United States and the disproportionate impact of the disease on African Americans.
GeoVax to Develop Vaccine Against Zika Virus
Marketwired - Wed Feb 03, 8:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has begun a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform. The company believes that it can rapidly advance a vaccine candidate to human clinical testing.
